The latest price target for BioRestorative Therapies (NASDAQ:BRTX) was reported by Roth MKM on August 14, 2024. The analyst firm set a price target for $18.00 expecting BRTX to rise to within 12 months (a possible 1145.67% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for BioRestorative Therapies (NASDAQ:BRTX) was provided by Roth MKM, and BioRestorative Therapies maintained their buy rating.

There is no last upgrade for BioRestorative Therapies

There is no last downgrade for BioRestorative Therapies.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioRestorative Therapies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioRestorative Therapies was filed on August 14, 2024 so you should expect the next rating to be made available sometime around August 14, 2025.

While ratings are subjective and will change, the latest BioRestorative Therapies (BRTX) rating was a maintained with a price target of $15.00 to $18.00. The current price BioRestorative Therapies (BRTX) is trading at is $1.45, which is out of the analyst’s predicted range.